123 (PB113) - Omomyc downregulates MYC transcriptional signature in preclinical models of solid tumours and shows long half-life in tumour tissue

Abstract

Background: The expression and function of the MYC family of oncoproteins are tightly regulated in normal cells, but it becomes deregulated in up to 70% of human cancers through a variety of mechanisms, functioning as a master modulator of the cancer transcriptome. Despite the broad therapeutic utility anticipated for a clinical MYC inhibitor, MYC remains considered undruggable, and so far, no direct MYC inhibitor has been approved for clinical use.